FAP and malignant colon neoplasm: As an illustration, with a 10-fold increase in FAP-binding affinity versus the reference FAP-4-1BBL molecule, the percentage of patients achieving at least 90% of the maximum pharmacological benefit would be expected to increase from 6% to 39% in the colon cancer indication.